# EDGAR Filing Document

**Accession Number:** 0001766600
**File Stem:** 0001171843-26-001503
**Filing Date:** 2026-3
**Character Count:** 46255
**Document Hash:** d925b294ec5d1475328bab445666a2a1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-001503.hdr.sgml**: 20260312

**ACCESSION NUMBER**: 0001171843-26-001503

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260312

**FILED AS OF DATE**: 20260312

**DATE AS OF CHANGE**: 20260312

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SNDL Inc.
- **CENTRAL INDEX KEY:** 0001766600
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39005
- **FILM NUMBER:** 26745594

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 17220 STONY PLAIN ROAD NW
- **STREET 2:** SUITE 101
- **CITY:** EDMONTON
- **PROVINCE COUNTRY:** Z4
- **BUSINESS PHONE:** 17809449994

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 17220 STONY PLAIN ROAD NW
- **STREET 2:** SUITE 101
- **CITY:** EDMONTON
- **PROVINCE COUNTRY:** Z4

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sundial Growers Inc.
- **DATE OF NAME CHANGE:** 20190131

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2026**

Commission File Number: **001-39005**

**SNDL Inc.**

(Translation of registrant's name into English)

**#101, 17220 Stony Plain Road NW Edmonton, AB T5S 1K6 Tel.: (780) 944-9994**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ ] &nbsp;&nbsp;&nbsp;&nbsp; Form 40-F [ X ]

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | <u>**&nbsp;&nbsp;&nbsp;&nbsp;SNDL Inc.&nbsp;&nbsp;&nbsp;&nbsp;**</u> |
|  | (Registrant) |
| Date: March 12, 2026 | <u>&nbsp;&nbsp;&nbsp;&nbsp;/s/ Alberto Paredero Quiros&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  | Alberto Paredero Quiros |
|  | Chief Financial Officer |

---

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| <u>**Exhibit Number**</u> | <u>**Description**</u> |
| [99.1](exh_991.htm) | [Press Release dated March 12, 2026](exh_991.htm) |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**SNDL Reports Fourth Quarter and Full Year 2025 Financial and Operational Results**

**The Company Reports Record Full-Year Income Statement Performance and Cash Generation**

EDMONTON, Alberta, March 12, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) ("**SNDL**" or the "**Company**") reported its financial and operational results for the full year and fourth quarter ended December 31, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated.

SNDL has also posted a supplemental investor presentation on its website, found at <u>https://sndl.com</u>.

The Company will hold a **conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, March 12, 2026.** The conference call details can be found below.

**MANAGEMENT HIGHLIGHTS**

* <u>Net revenue</u> for the fourth quarter of 2025 was $252.5 million, and $946.4 million for the full year of 2025, representing decrease of (2.0)% and growth of +2.8%, respectively, when compared to the same periods of the previous year. The full year represents a new record for the corporation, driven by strong growth from our combined Cannabis business of +11.4%.

* <u>Gross profit</u> also reached new records, with $70.2 million in the fourth quarter of 2025, and $258.6 million for the full year, representing growth of +2.1% and +7.6%, respectively, when compared to the same periods of the previous year.

* <u>Gross margin</u><sup><u>(1)</u></sup> of 27.8% in the fourth quarter of 2025 and 27.3% for the full year are also new records, representing improvements of +1.1 and +1.2 percentage points, respectively, when compared to the same periods of the previous year.

* <u>Operating</u> <u>Income</u> of $11.8 million for the fourth quarter of 2025 and $(6.3) million for the full year also represent new records, driven by gross margin progression and SG&A efficiency improvements. Excluding restructuring-related charges, Adjusted Operating Income totaled $12.8 million in the fourth quarter of 2025 and, for the first time in the Company's history, reached break-even for the full year at $0.1 million.

* <u>Cash flow</u> was positive by $11.7 million in the fourth quarter of 2025 and $33.9 million for the full year, driven by contributions from operating activities. The full year also benefited from interest payments and proceeds from investments. 

* <u>Free cash flow</u><sup><u>(1)</u></sup> was positive in the fourth quarter of 2025 at $10.2 million and for the full year at $18.0 million, with full-year results more than doubling the prior year's record and reflecting continued operating momentum.

"2025 represents another step forward in financial performance and strategic focus for SNDL. We are pleased to report new records across our income statement and free cash flow, while continuing to transform our business to support long-term, sustainable, and profitable growth," said Zach George, Chief Executive Officer of SNDL. "We are strengthening our performance culture and organizational capabilities, providing a solid foundation as we continue to raise the bar toward our vision of becoming a global leader in our industry."

Beyond our financial results, during the fourth quarter of 2025 and through the first months of 2026 to date, we continued to advance several key initiatives that further strengthen our foundation for long-term success and shareholder value creation, including:

* **SunStream restructuring progress**: As U.S. cannabis rescheduling gains momentum, the restructuring of the Parallel and Skymint investments continues to advance toward completion, with only a limited number of remaining requirements outstanding.

* **Strategic organic investments**: Capital expenditures increased from $8.6 million in 2024 to $12.8 million in 2025, including $4.0 million in the fourth quarter. The majority of these investments were directed toward new store openings across our Cannabis and Liquor Retail segments.

* **Acquisition of 1CM retail stores**: On January 6, 2026, SNDL announced the completion of the acquisition of five *Cost Cannabis* retail stores located in Alberta and Saskatchewan from 1CM Inc. ("1CM"). We continue to support the regulatory approval process in Ontario for the remaining 27 stores.

* **Share buybacks**: Between December 2025 and March 9, 2026, the Company repurchased 4.3 million common shares for cancellation, bringing the total numbers of shares repurchased since the fourth quarter of 2024 to 15.1 million.

* **Progress towards simplification & focus**: With more than $20 million in annualized savings delivered to date, the completion of the third and final phase of the corporate restructuring program, announced in mid-2024 and expected to conclude in the second quarter of 2026, positions the Company to exceed the program's targeted savings. In addition, we are days away from completing full ERP consolidation, which will further enhance operational visibility and process efficiency.

With $252.2 million of unrestricted cash and no debt as of December 31, 2025, and exposure across the Canadian, U.S., and European markets, we are uniquely positioned to deploy capital into both organic and inorganic opportunities to further enhance our portfolio and accelerate growth. Disciplined capital allocation remains a key priority for our management team in 2026, alongside continued execution on efficiency initiatives and profitability-enhancing actions.

**TOTAL COMPANY HIGHLIGHTS**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** |  | **Year ended December 31** | **Year ended December 31** | **Year ended December 31** |  |
| **($000s)** | **2025** | **2024** | **% Change** |  | **2025** | **2024** | **% Change** |  |
| **<u>IFRS Financial Measures</u>** |  |  |  |  |  |  |  |  |
| Net revenue | **252499** | 257679 | -2.0 | % | **946401** | 920448 | 2.8 | % |
| Gross profit | **70229** | 68799 | 2.1 | % | **258648** | 240331 | 7.6 | % |
| Operating income (loss) | **11751** | (76089) | 115.4 | % | **(6349)** | (103811) | 93.9 | % |
| Change in cash and cash equivalents | **11662** | (44617) | 126.1 | % | **33884** | 23318 | 45.3 | % |
| **<u>Non-IFRS Financial Measures</u><sup><u>(1)</u></sup>** |  |  |  |  |  |  |  |  |
| Gross margin | **27.8%** | 26.7% | 1.1 | pp | **27.3%** | 26.1% | 1.2 | pp |
| Adjusted operating income (loss) | **12801** | (60472) | 121.2 | % | **88** | (86144) | 100.1 | % |
| Free cash flow | **10218** | 11625 | -12.1 | % | **17951** | 8872 | 102.3 | % |

---

<sup>(1) Gross Margin is a supplementary financial measure calculated by dividing Gross Profit by Net Revenue. Adjusted operating income (loss) and Free Cash Flow are specified financial measures that do not have a standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures reported by other companies. See "Non-IFRS Measures" section below for further information.</sup>

**BUSINESS SEGMENT HIGHLIGHTS**

SNDL operates and reports its business through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. Additionally, a consolidated total for Cannabis is presented, encompassing the combined results of the two Cannabis segments, along with the revenue elimination associated with the Cannabis Operations sales to the provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale. Corporate and Shared Service expenses are reported as "Corporate".

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Year ended December 31** | **Year ended December 31** | **Year ended December 31** |
| <br>**($000s)** | **2025** | **2024** | **% Change** | **2025** | **2024** | **% Change** |
| **<u>Net Revenue</u>** |  |  |  |  |  |  |
| &nbsp;&nbsp;*Cannabis Retail* | **83282** | 83170 | 0.1% | **330242** | 311689 | 6.0% |
| &nbsp;&nbsp;*Cannabis Operations* | **37112** | 37092 | 0.1% | **144656** | 109470 | 32.1% |
| &nbsp;&nbsp;*Intersegment Eliminations* | **(16738)** | (16663) | -0.5% | **(68129)** | (55970) | -21.7% |
| Total Cannabis | **103656** | 103599 | 0.1% | **406769** | 365189 | 11.4% |
| Liquor Retail | **148843** | 154080 | -3.4% | **539632** | 555259 | -2.8% |
| Investments | **—** |  | 0.0% | **—** |  | 0.0% |
| Total | **252499** | 257679 | -2.0% | **946401** | 920448 | 2.8% |
| **<u>Operating Income</u>** |  |  |  |  |  |  |
| &nbsp;&nbsp;*Cannabis Retail* | **8003** | (8997) | 189.0% | **30332** | (1742) | 1841.2% |
| &nbsp;&nbsp;*Cannabis Operations* | **1874** | 4391 | -57.3% | **(1754)** | 2663 | -165.9% |
| Total Cannabis | **9877** | (4606) | 314.4% | **28578** | 921 | 3002.9% |
| Liquor Retail | **12240** | 12325 | -0.7% | **36516** | 34781 | 5.0% |
| Investments | **2434** | (63724) | 103.8% | **4209** | (50013) | 108.4% |
| Corporate | **(12800)** | (20084) | 36.3% | **(75652)** | (89500) | 15.5% |
| Total | **11751** | (76089) | 115.4% | **(6349)** | (103811) | 93.9% |
| **<u>Adjusted Operating Income</u>** |  |  |  |  |  |  |
| &nbsp;&nbsp;*Cannabis Retail* | **8003** | 6003 | 33.3% | **30332** | 13258 | 128.8% |
| &nbsp;&nbsp;*Cannabis Operations* | **2154** | 4439 | -51.5% | **2454** | 3091 | -20.6% |
| Total Cannabis | **10157** | 10442 | -2.7% | **32786** | 16349 | 100.5% |
| Liquor Retail | **12240** | 12325 | -0.7% | **36516** | 34781 | 5.0% |
| Investments | **2434** | (63724) | 103.8% | **4209** | (50013) | 108.4% |
| Corporate | **(12030)** | (19515) | 38.4% | **(73423)** | (87261) | 15.9% |
| Total | **12801** | (60472) | 121.2% | **88** | (86144) | 100.1% |

---

 **Liquor Retail** 

SNDL is Canada's largest private sector liquor retailer, operating at March 11, 2026 in 167 locations, predominantly in Alberta, under its three retail banners: "Wine and Beyond" (15), "Liquor Depot" (19), and "Ace Liquor" (133).

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** |  | **Year ended December 31** | **Year ended December 31** | **Year ended December 31** |  |
| **($000s)** | **2025** | **2024** | **% Change** |  | **2025** | **2024** | **% Change** |  |
| Net revenue | **148843** | 154080 | -3.4 | % | **539632** | 555259 | -2.8 | % |
| Gross profit | **38658** | 38236 | 1.1 | % | **139651** | 139706 | 0.0 | % |
| Gross margin | **26.0%** | 24.8% | 1.2 | pp | **25.9%** | 25.2% | 0.7 | pp |
| Operating income | **12240** | 12325 | -0.7 | % | **36516** | 34781 | 5.0 | % |
| Adjusted operating income | **12240** | 12325 | -0.7 | % | **36516** | 34781 | 5.0 | % |

---

* Net revenue for Liquor Retail continued to decline in the fourth quarter of 2025, as market demand softness persisted and impacted same-store sales <sup>(2)</sup>, which decreased by -4.0% in the fourth quarter and -2.3% for the full year. During the fourth quarter of 2025 two new Wine & Beyond stores were opened in Regina (SK) and Calgary (AB) as part of the plan to expand our successful W&B format. <sup>(2) Same-store sales is a specified financial measure that does not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures used by other companies. See "Non-IFRS Measures" section below for further information.</sup>

* Operating Income remained virtually flat despite revenue declines, driven by pricing and mix management strategies that supported Gross Margin improvement, including the expansion of private label offerings at accretive margins, as well as cost optimization and in-store productivity initiatives.

**Cannabis Retail**

SNDL is one of Canada's largest private-sector cannabis retailer, operating at March 11, 2026 in 192 locations under its three retail banners: "Value Buds" (127), "Spiritleaf" (60, of which 4 are corporate stores and 56 are franchise stores), and "Cost Cannabis" (5). The Company's Cannabis Retail strategy is based on several pillars, including the quality of its store locations, its range of products, and the unique experiences provided to customers. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** |  | **Year ended December 31** | **Year ended December 31** | **Year ended December 31** |  |
| **($000s)** | **2025** | **2024** | **% Change** |  | **2025** | **2024** | **% Change** |  |
| Net revenue | **83282** | 83170 | 0.1 | % | **330242** | 311689 | 6.0 | % |
| Gross profit | **22079** | 20490 | 7.8 | % | **86053** | 78827 | 9.2 | % |
| Gross margin | **26.5%** | 24.6% | 1.9 | pp | **26.1%** | 25.3% | 0.8 | pp |
| Operating income | **8003** | (8997) | 189.0 | % | **30332** | (1742) | 1841.2 | % |
| Adjusted operating income | **8003** | 6003 | 33.3 | % | **30332** | 13258 | 128.8 | % |

---

* Net revenue for Cannabis Retail reached a new full-year record as our Value Buds banner continued to gain market share. Same-store sales grew +3.9% for the full year, although declined by (0.7)% in the fourth quarter of 2025 driven by a market slow-down. Subsequent to year-end, the Company completed the acquisition and integration of five "Cost Cannabis" stores located in Alberta and Saskatchewan from 1CM.

* Operating Income shows strong growth in both the fourth quarter of 2025 and full year, supported by continuous gross margin expansion, including the achievement of a new full-year record, and improved SG&A cost efficiencies. The year-on-year comparison is impacted by a $15 million Spiritleaf intangible asset impairment recorded in the fourth quarter of 2024, related to the conversion of several Spiritleaf stores to Value Buds. Adjusted Operating Income excludes this Spiritleaf intangible impairment and more clearly reflects the normalized improvement in the segment's underlying operating profitability.

**Cannabis Operations** 

SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities and plans to continue evolving toward a cost-effective cultivation and manufacturing operation, the Cannabis Operations segment is a key enabler of SNDL's vertical integration strategy.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** |  | **Year ended December 31** | **Year ended December 31** | **Year ended December 31** |  |
| **($000s)** | **2025** | **2024** | **% Change** |  | **2025** | **2024** | **% Change** |  |
| Net revenue | **37112** | 37092 | 0.1 | % | **144656** | 109470 | 32.1 | % |
| Gross profit | **9492** | 10073 | -5.8 | % | **32944** | 21798 | 51.1 | % |
| Gross margin | **25.6%** | 27.2% | -1.6 | pp | **22.8%** | 19.9% | 2.9 | pp |
| Operating income (loss) | **1874** | 4391 | -57.3 | % | **(1754)** | 2663 | -165.9 | % |
| Adjusted operating income (loss) | **2154** | 4439 | -51.5 | % | **2454** | 3091 | -20.6 | % |

---

* Cannabis Operations reported a new full-year Net Revenue record. This expansion is mainly driven by edibles, following Indiva's acquisition in the fourth quarter of 2024, as well as international sales growing from $3.6 million in 2024 to $12.6 million in 2025.

* While the segment achieved a new full-year Gross Margin record, results were impacted in the third quarter of 2025 by inventory write-offs and valuation adjustments related to the cultivation ramp-up, and the fixed-asset write-off of the idle Stellarton facility, as well as by restructuring charges related to the Indiva integration mostly during the first quarter of 2025.

**Investments**

* As of December 31, 2025, the Company has deployed capital to a portfolio of cannabis-related investments with a carrying value of $397.6 million, including $385.5 million to SunStream Bancorp Inc. ("**SunStream**"). This carrying value was reduced by $5.6 million during the fourth quarter of 2025, primarily due to a decrease in the USD to CAD exchange rate from 1.3921 on September 30, 2025 to 1.3706 on December 31, 2025.

* The previously disclosed restructuring process relating to Skymint continues. SNDL is awaiting an update from the Michigan Supreme Court expected in Q3 2026, which is expected to determine whether the court will accept the case for further review. Timing and outcomes remain uncertain and subject to court process and other factors.

* The previously disclosed restructuring process relating to Parallel continues. On February 4, 2025, the Florida Department of Health approved the transfer of Parallel's license, representing an important milestone in completing Parallel's restructuring process. In December 2025, a settlement was reached resolving the final remaining litigation, and SNDL currently expects the strict foreclosure process to close in Q3 2026, subject to completion of remaining steps, satisfaction of applicable conditions, and any required approvals.

* SunStream continues to hold exposure to The Cannabist Company Holdings Inc. ("Cannabist") through the senior secured notes, with an aggregate position of approximately $35 million and estimated NAV of $28.3 million. Forecasted liquidity challenges have led Cannabist to pursue asset divestitures. Based on scenarios reviewed by Cannabist's advisors, SNDL believes there is a pathway to full recovery of the senior secured notes relative to current NAV estimates, although outcomes remain subject to execution risk and other uncertainties.

* The investment portfolio generated a positive operating income of $2.4 million in the fourth quarter of 2025 and $4.2 million in the full year, primarily driven by interests earned from our cash accounts.

* On December 18, 2025, U.S. President Donald Trump issued an executive order directing the Department of Justice to expedite the process to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act. The order did not itself reclassify cannabis but instead directed regulators to finalize an ongoing rulemaking process. If finalized, while not constituting federal legalization, reclassification is expected to improve tax exposure for companies operating in the U.S. through the elimination of Section 280E, expand medical research and regulatory clarity, and incrementally enhance access to capital. These developments would meaningfully improve industry economics and investability.

**Equity Position** 

* $649.9 million of unrestricted cash, marketable securities and investments, including investments in equity-accounted investees, and no outstanding debt at December 31, 2025, resulting in a net book value of $1.1 billion.

* The board of directors of the Company has approved the renewal of its Share Repurchase Program upon the expiry of its share repurchase program on November 20, 2025.

* For the three months ended December 31, 2025, the Company purchased for cancellation 136,362 common shares at a weighted average price, excluding commissions, of US$1.64 per share. Subsequent to year-end, between January 1, 2026 and March 9, 2026 the Company purchased and cancelled an additional 4,153,358 common shares at a weighted average price, excluding commissions, of US$1.56 per share. SNDL will continue to evaluate opportunities to utilize the program to the extent that management believes it is in the best interest of SNDL's shareholders. As a reminder, since the fourth quarter of 2024 the Company has repurchased 15,055,627 common shares for cancellation.

This press release is intended to be read in conjunction with the Company's consolidated financial statements and the notes thereto for the years ended December 31, 2025 and 2024, and the accompanying Management's Discussion and Analysis. These documents are available under the Company's profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.shtml.

**CONFERENCE CALL** 

The Company will hold a **conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Thursday, March 12, 2026.**

**WEBCAST ACCESS**

To access the live webcast of the call, please visit the following link:

**<u>https://edge.media-server.com/mmc/p/aps8jm4e</u>**

**REPLAY**

A replay of the webcast will be available at **<u>https://sndl.com/financials/quarterly-results/default.aspx</u>**

**ABOUT SNDL INC.** 

SNDL Inc. (NASDAQ: SNDL, CSE: SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf and Cost Cannabis. With products available in licensed cannabis retail locations nationally, SNDL's consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future and Bhang Chocolate. SNDL's investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information, please visit <u>www.sndl.com</u>

**For more information:**

Tomas Bottger

SNDL Inc.

O: 1.587.327.2017

E: <u>investors@sndl.com</u>

**Forward-Looking Information Cautionary Statement** 

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"), including, but not limited to, statements regarding the Company's operational goals, plans and key priorities, the Company's ability to deploy capital and the expected benefits thereof, the growth opportunities available to SNDL and the expected benefits thereof, expectations with respect to the 1CM transaction, including the satisfaction of certain regulatory approvals, the progress of the Sunstream restructurings, expectations with respect to the Skymint and Parallel restructuring processes, SNDL's corporate restructuring program, including the timing to conclude the restructuring and expected benefits thereof, the expected benefits of the ERP consolidation, SNDL's ability to recover the senior secured notes held in Cannabist, the potential impact of reclassifying cannabis from Schedule I to Schedule III under the Controlled Substances Act, the Company's retail strategy, and any other potential forms of shareholder value creation. Forward-looking statements are frequently characterized by words such as "aim", "anticipate", "assume", "believe", "contemplate", "continue", "could", "due", "estimate", "expect", "goal", "intend", "may", "objective", "plan", "predict", "potential", "positioned", "pioneer", "seek", "should", "target", "will", "would", and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company's business and the industry in which it operates and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see "Risk Factors" in the Company's Annual Information Form dated March 11, 2026, and the risk factors included in our other public disclosure documents for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

---

| | | |
|:---|:---|:---|
| **Condensed Consolidated Statement of Loss and Comprehensive Loss**<br> (Expressed in thousands of Canadian dollars, except per share amounts) | **Condensed Consolidated Statement of Loss and Comprehensive Loss**<br> (Expressed in thousands of Canadian dollars, except per share amounts) | **Condensed Consolidated Statement of Loss and Comprehensive Loss**<br> (Expressed in thousands of Canadian dollars, except per share amounts) |
|  | **Year ended**<br>**December 31** | **Year ended**<br>**December 31** |
|  | **2025** | 2024 |
| **Net revenue** | **946401** | 920448 |
| Cost of sales | **687753** | 680117 |
| **Gross profit** | **258648** | 240331 |
| Investment income | **7814** | 15551 |
| Share of loss of equity-accounted investees | **(3605)** | (65459) |
| General and administrative | **182162** | 187243 |
| Sales and marketing | **14565** | 12004 |
| Depreciation and amortization | **51948** | 54250 |
| Share-based compensation | **13905** | 20037 |
| Restructuring costs | **3337** | 2667 |
| Asset impairment, net | **2618** | 17317 |
| Research and development | **489** | 346 |
| Loss on disposition of assets | **182** | 370 |
| **Operating loss** | **(6349)** | (103811) |
| Other expenses, net | **(9425)** | (1798) |
| Loss before income tax | **(15774)** | (105609) |
| Income tax recovery | **—** | 9405 |
| **Net loss** | **(15774)** | (96204) |
| Equity-accounted investees - share of other comprehensive (loss) income | **(19233)** | 31489 |
| Investments at fair value through other comprehensive income ("FVOCI") - change in fair value | **5358** | 1864 |
| **Comprehensive loss** | **(29649)** | (62851) |
| **Net loss attributable to:** |  |  |
| Owners of the Company | **(15774)** | (94796) |
| Non-controlling interest | **—** | (1408) |
|  | **(15774)** | (96204) |
| **Comprehensive loss attributable to:** |  |  |
| Owners of the Company | **(29649)** | (61443) |
| Non-controlling interest | **—** | (1408) |
|  | **(29649)** | (62851) |
| Net loss per common share attributable to owners of the Company |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | $**(0.06)** | $(0.36) |

---

---

| | | |
|:---|:---|:---|
| **Condensed Consolidated Statement of Financial Position**<br> (Expressed in thousands of Canadian dollars) | **Condensed Consolidated Statement of Financial Position**<br> (Expressed in thousands of Canadian dollars) | **Condensed Consolidated Statement of Financial Position**<br> (Expressed in thousands of Canadian dollars) |
| As at | **December 31, 2025** | December 31, 2024 |
| **Assets** |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | **252243** | 218359 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | **20081** | 19815 |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | **84** | 139 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | **27643** | 28118 |
| &nbsp;&nbsp;&nbsp;&nbsp;Biological assets | **3120** | 1187 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | **126877** | 127919 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and deposits | **15566** | 16860 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments | **484** | 27560 |
| &nbsp;&nbsp;&nbsp;&nbsp;Assets held for sale | **746** | 19051 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment in subleases | **2775** | 2832 |
|  | **449619** | 461840 |
| Non-current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term deposits and receivables | **4526** | 3679 |
| &nbsp;&nbsp;&nbsp;&nbsp;Right of use assets | **138353** | 115435 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment | **151900** | 145810 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment in subleases | **11643** | 15354 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets | **58520** | 61325 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments | **11574** | 8427 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-accounted investees | **385534** | 413124 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | **124248** | 124248 |
| **Total assets** | **1335917** | 1349242 |
| **Liabilities** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | **56747** | 56275 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease liabilities | **35462** | 34256 |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivative warrants | **—** | 26 |
|  | **92209** | 90557 |
| Non-current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease liabilities | **134471** | 118017 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | **8041** | 7312 |
| Total liabilities | **234721** | 215886 |
| **Shareholders' equity** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share capital | **2310398** | 2346728 |
| &nbsp;&nbsp;&nbsp;&nbsp;Warrants | **306** | 667 |
| &nbsp;&nbsp;&nbsp;&nbsp;Contributed surplus | **54038** | 57156 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | **(1302441)** | (1323965) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income ("AOCI") | **38895** | 52770 |
| Total shareholders' equity | **1101196** | 1133356 |
| **Total liabilities and shareholders' equity** | **1335917** | 1349242 |

---

---

| | | |
|:---|:---|:---|
| **Condensed Consolidated Statement of Cash Flows**<br> (Expressed in thousands of Canadian dollars) | **Condensed Consolidated Statement of Cash Flows**<br> (Expressed in thousands of Canadian dollars) | **Condensed Consolidated Statement of Cash Flows**<br> (Expressed in thousands of Canadian dollars) |
|  | **Year ended**<br>**December 31** | **Year ended**<br>**December 31** |
|  | **2025** | 2024 |
| **Cash provided by (used in):** |  |  |
| Operating activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss for the period | **(15774)** | (96204) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax recovery | **—** | (9405) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest and fee income | **(7436)** | (15637) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of biological assets | **(2322)** | 675 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of inventory sold | **1252** | (1567) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | **13905** | 20037 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **56271** | 56711 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on disposition of assets | **182** | 370 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory impairment and obsolescence | **2671** | 3707 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finance costs, net | **6693** | 7161 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in estimate of fair value of derivative warrants | **(26)** | (4374) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized foreign exchange loss | **614** | 108 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction costs | **—** | 164 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bargain purchase gain | **—** | (5456) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asset impairment, net | **2618** | 17317 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share of loss of equity-accounted investees | **3605** | 65459 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized (gain) loss on marketable securities | **(378)** | 86 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions to marketable securities | **433** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income distributions from equity-accounted investees | **68** | 10715 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest received | **7109** | 12494 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in non-cash working capital | **1432** | (7447) |
| **Net cash provided by operating activities** | **70917** | 54914 |
| Investing activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions to property, plant and equipment | **(12811)** | (8615) |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions to intangible assets | **—** | (2404) |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions to investments | **(16414)** | (36155) |
| &nbsp;&nbsp;&nbsp;&nbsp;Principal payments from investments | **27488** | 13538 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from disposal of investments | **18090** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital refunds from equity-accounted investees | **—** | 168 |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital distributions from equity-accounted investees | **4684** | 89758 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from disposal of property, plant and equipment | **813** | 734 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisitions, net of cash acquired | **(3000)** | (39644) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in non-cash working capital | **(1396)** | 383 |
| **Net cash provided by investing activities** | **17454** | 17763 |
| Financing activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in restricted cash | **(267)** | 76 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments on lease liabilities, net | **(39245)** | (36952) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common shares | **(15348)** | (13219) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of shares, net of costs | **—** | (59) |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common shares by subsidiaries | **—** | 174 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in non-cash working capital | **373** | 621 |
| **Net cash used in financing activities** | **(54487)** | (49359) |
| Change in cash and cash equivalents | **33884** | 23318 |
| Cash and cash equivalents, beginning of period | **218359** | 195041 |
| Cash and cash equivalents, end of period | **252243** | 218359 |

---

 **NON-IFRS MEASURES**

Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures reported by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS. These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company's operating results in the same manner as the management team.

**ADJUSTED OPERATING INCOME (LOSS)** Adjusted operating income (loss) is a non-IFRS financial measure which the Company uses to evaluate its operating performance in a similar manner to its management team. The Company defines adjusted operating income (loss) as operating income (loss) less restructuring costs (recovery), goodwill and intangible asset impairments and asset impairments triggered by restructuring activities.

The following tables reconcile adjusted to un-adjusted operating income (loss) for the periods noted.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **($000s)** | **Cannabis**<br>**Retail** | **Cannabis**<br>**Operations** | **Cannabis**<br>**Total** | **Liquor**<br>**Retail** | **Investments** | **Corporate** | **Total** |
| **Three months ended December 31, 2025** | **Three months ended December 31, 2025** | **Three months ended December 31, 2025** | **Three months ended December 31, 2025** | **Three months ended December 31, 2025** | **Three months ended December 31, 2025** | **Three months ended December 31, 2025** | **Three months ended December 31, 2025** |
| Operating income (loss) | 8003 | 1874 | 9877 | 12240 | 2434 | (12800) | 11751 |
| Adjustments: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring costs |  | 280 | 280 |  |  | 770 | 1050 |
| &nbsp;&nbsp;Impairments triggered by restructuring |  |  |  |  |  |  |  |
| Adjusted operating income (loss) | **8003** | **2154** | **10157** | **12240** | **2434** | **(12030)** | **12801** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **($000s)** | **Cannabis**<br>**Retail** | **Cannabis**<br>**Operations** | **Cannabis**<br>**Total** | **Liquor**<br>**Retail** | **Investments** | **Corporate** | **Total** |
| **Year ended December 31, 2025** | **Year ended December 31, 2025** | **Year ended December 31, 2025** | **Year ended December 31, 2025** | **Year ended December 31, 2025** | **Year ended December 31, 2025** | **Year ended December 31, 2025** | **Year ended December 31, 2025** |
| Operating income (loss) | 30332 | (1754) | 28578 | 36516 | 4209 | (75652) | (6349) |
| Adjustments: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring costs |  | 1108 | 1108 |  |  | 2229 | 3337 |
| &nbsp;&nbsp;Impairments triggered by restructuring |  | 3100 | 3100 |  |  |  | 3100 |
| Adjusted operating income (loss) | **30332** | **2454** | **32786** | **36516** | **4209** | **(73423)** | **88** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **($000s)** | **Cannabis**<br>**Retail** | **Cannabis**<br>**Operations** | **Cannabis**<br>**Total** | **Liquor**<br>**Retail** | **Investments** | **Corporate** | **Total** |
| **Three months ended December 31, 2024** | **Three months ended December 31, 2024** | **Three months ended December 31, 2024** | **Three months ended December 31, 2024** | **Three months ended December 31, 2024** | **Three months ended December 31, 2024** | **Three months ended December 31, 2024** | **Three months ended December 31, 2024** |
| Operating income (loss) | (8997) | 4391 | (4606) | 12325 | (63724) | (20084) | (76089) |
| Adjustments: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring costs (recovery) |  | 48 | 48 |  |  | 569 | 617 |
| &nbsp;&nbsp;Goodwill and intangible asset impairments | 15000 |  | 15000 |  |  |  | 15000 |
| Adjusted operating income (loss) | **6003** | **4439** | **10442** | **12325** | **(63724)** | **(19515)** | **(60472)** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **($000s)** | **Cannabis**<br>**Retail** | **Cannabis**<br>**Operations** | **Cannabis**<br>**Total** | **Liquor**<br>**Retail** | **Investments** | **Corporate** | **Total** |
| **Year ended December 31, 2024** | **Year ended December 31, 2024** | **Year ended December 31, 2024** | **Year ended December 31, 2024** | **Year ended December 31, 2024** | **Year ended December 31, 2024** | **Year ended December 31, 2024** | **Year ended December 31, 2024** |
| Operating income (loss) | (1742) | 2663 | 921 | 34781 | (50013) | (89500) | (103811) |
| Adjustments: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Restructuring costs |  | 428 | 428 |  |  | 2239 | 2667 |
| &nbsp;&nbsp;Goodwill and intangible asset impairments | 15000 |  | 15000 |  |  |  | 15000 |
| Adjusted operating income (loss) | **13258** | **3091** | **16349** | **34781** | **(50013)** | **(87261)** | **(86144)** |

---

 **GROSS MARGIN** Gross margin is a supplementary financial measure calculated as gross profit divided by net revenue for the periods presented. This measure evaluates the underlying profitability of our operations and provides useful information about the Company's ability to price products effectively, manage input costs, drive operating efficiencies, and compare results across periods and business segments

**FREE CASH FLOW**

Free cash flow is a non-IFRS financial measure which the Company uses to evaluate its financial performance, providing information which management believes to be useful in understanding and evaluating the Company's ability to generate positive cash flows as it removes cash used for non-operational items. The Company defines free cash flow as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), changes to debt instruments, changes to long-term investments, net cash used for acquisitions plus cash provided by dispositions (if any).

The following table reconciles free cash flow to change in cash and cash equivalents for the periods noted.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** <br>**December 31** | **Three months ended** <br>**December 31** | **Year ended**<br>**December 31** | **Year ended**<br>**December 31** |
| **($000s)** | **2025** | 2024 | **2025** | 2024 |
| Change in cash and cash equivalents | **11662** | (44617) | **33884** | 23318 |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common shares | **314** | 13219 | **15348** | 13219 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes to long-term investments | **(3758)** | 5033 | **(34281)** | (67309) |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisitions, net of cash acquired | **2000** | 37990 | **3000** | 39644 |
| Free cash flow | **10218** | 11625 | **17951** | 8872 |

---

 **SAME STORE SALES** Same store sales is a non-IFRS financial measure which the Company uses to evaluate its financial performance in its retail segments. Same store sales provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company's sales trends excluding the effect of the opening and closure of stores.

Same store sales refers to the revenue generated by the Company's existing retail locations during the current and prior comparison periods.

**ADJUSTED EBITDA** Adjusted EBITDA is a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts, and others to aid in understanding and evaluating the Company's operating results. The Company defines adjusted EBITDA as net earnings (loss) before inventory and biological assets fair value and impairment adjustments, share of (gain) loss of equity-accounted investees, depreciation and amortization, share-based compensation expense, restructuring costs, asset impairment, gain or loss on disposal of property, other expenses, net, income tax expense (recovery) and excluding non-recurring items including enterprise resource planning ("ERP") implementation costs and litigation settlements, net of recoveries.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** <br>**December 31** | **Three months ended** <br>**December 31** | **Year ended**<br>**December 31** | **Year ended**<br>**December 31** |
| **($000s)** | **2025** | 2024 | **2025** | 2024 |
| Net earnings (loss) | **9367** | (67249) | **(15774)** | (96204) |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory and biological assets fair value and impairment adjustments | **184** | (179) | **1601** | 2615 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share of (gain) loss of equity-accounted investees | **(782)** | 66458 | **3605** | 65459 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **12872** | 13199 | **51948** | 54250 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | **(1285)** | 4609 | **13905** | 20037 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring costs | **1050** | 617 | **3337** | 2667 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset impairment | **(353)** | 15000 | **2618** | 17317 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on disposition of PP&E | **236** | (71) | **182** | 370 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other expenses, net | **2384** | (2282) | **9425** | 1798 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax recovery | **—** | (6558) | **—** | (9405) |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-recurring items | **75** | 181 | **(621)** | 882 |
| Adjusted EBITDA | **23748** | 23725 | **70226** | 59786 |

---